Calidi Biotherapeutics to Present RedTail Platform at H.C. Wainwright Global Investment Conference
TL;DR
Calidi Biotherapeutics' CEO presentation at the H.C. Wainwright conference highlights their RedTail platform's potential to deliver competitive advantages in treating metastatic cancers through systemic administration.
Calidi's RedTail platform uses engineered enveloped oncolytic viruses to shield from immune clearance, induce tumor lysis, and deliver genetic medicines to metastatic sites via systemic administration.
Calidi's innovative cancer therapy platform aims to improve treatment outcomes for patients with metastatic diseases, potentially making tomorrow better for those facing high unmet medical needs.
Calidi Biotherapeutics is pioneering systemic delivery of oncolytic viruses to target metastatic cancers, with their lead candidate currently in IND-enabling studies for multiple tumor types.
Found this article helpful?
Share it with your network and spread the knowledge!
Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York. An on-demand presentation will be available starting September 5 at 7 a.m. ET, providing investors and industry professionals with detailed insights into the company's groundbreaking RedTail platform technology.
The presentation will focus on Calidi's proprietary RedTail platform, an engineered enveloped oncolytic virus system designed specifically for systemic administration and targeting of metastatic cancer sites. This advanced technology represents a significant advancement in immuno-oncology, as it is engineered to protect the therapeutic virus from immune clearance while enabling effective delivery of genetic medicines to distal disease locations. The platform's ability to induce tumor lysis and deliver potent gene therapies through systemic administration addresses critical challenges in treating metastatic cancers.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to transform cancer treatment. The company's lead candidate from the RedTail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies for intratumoral and localized administration, focusing on injectable cancer indications that could benefit from more targeted treatment approaches.
The implications of this technology are substantial for the oncology field and cancer patients worldwide. The ability to systemically deliver oncolytic viruses that can evade immune detection and reach metastatic sites could represent a paradigm shift in cancer treatment. Current treatments often struggle to effectively target metastatic disease, which remains a leading cause of cancer mortality. Calidi's approach potentially offers a more comprehensive treatment strategy that addresses both primary tumors and distant metastases.
For investors and the pharmaceutical industry, Calidi's presentation at this prestigious conference provides valuable insight into the company's progress and the potential market impact of its technology. The H.C. Wainwright Global Investment Conference attracts significant attention from institutional investors, analysts, and industry leaders, making it an ideal platform for showcasing innovative medical technologies. The availability of an on-demand presentation starting September 5 ensures broader accessibility for interested parties who cannot attend in person.
The latest news and updates relating to CLDI are available in the company's newsroom at https://ibn.fm/CLDI. This development represents an important milestone for Calidi Biotherapeutics as it continues to advance its novel cancer treatment platform through clinical development stages.
Curated from InvestorBrandNetwork (IBN)
